克拉霉素和甲硝唑耐药MIC水平对幽门螺杆菌根除治疗的影响
该研究为一项治疗试验的事后分析,纳入1006例接受一线序贯治疗且经Etest药敏检测的幽门螺杆菌感染患者,按MIC值将耐药分为低水平和高水平。结果显示,双耐药且两种抗生素MIC均高时才降低根除率(83.9%),而低水平双耐药根除率仍高(92.7%);单耐药无论MIC高低与敏感菌株疗效无显著差异。
要点
- 双耐药时,仅当两种抗生素MIC均高才显著降低根除率。
- 低水平双耐药根除率仍高,单耐药与敏感菌株疗效无显著差异。
- MIC水平影响幽门螺杆菌根除治疗结局,耐药需结合MIC值评估。
核心结论
- 克拉霉素或甲硝唑耐药MIC水平影响幽门螺杆菌治疗结局,双耐药且至少一种抗生素MIC高时耐药才具临床相关性。
研究设计与样本
- 治疗试验的事后分析,纳入1006例接受一线序贯治疗且经Etest药敏检测的幽门螺杆菌感染患者。
主要发现
- 520例(51.7%)为敏感菌株,136例(13.5%)为克拉霉素耐药,144例(14.3%)为甲硝唑耐药,206例(20.5%)为双耐药。
- 双耐药且MIC水平低时根除率为38/41(92.7%),双耐药且两种抗生素MIC均高时根除率为94/112(83.9%)。
- 单耐药患者无论MIC值如何,根除率与敏感菌株患者无显著差异。
关键数值与推荐
- 克拉霉素低耐药MIC为>0.5至≤8 mg/L,高耐药MIC为>8至256 mg/L。
- 甲硝唑低耐药MIC为>8至≤32 mg/L,高耐药MIC为>32至256 mg/L。
临床怎么用
- 临床解读幽门螺杆菌药敏结果时需关注MIC水平,双耐药且至少一种抗生素MIC高时可能影响序贯疗法根除率。
局限性
- 本研究为事后分析,结果需在前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antimicrobial resistance to clarithromycin and metronidazole significantly affects the cure rate of standard therapies for Helicobacter pylori infection. We tested whether different MIC levels of resistance to these antibiotics play a role in therapeutic efficacy. METHODS: This was a post hoc analysis of data from a therapeutic trial in which patients with antibiotic susceptibility testing (Etest) received first-line sequential therapy. The level of antibiotic resistance was classified according to MIC values into low (MIC from >0.5 to ≤8 for clarithromycin, and from >8 to ≤32 for metronidazole) and high (MIC from >8 to 256 mg/L for clarithromycin, and from >32 to 256 mg/L for metronidazole). RESULTS: Data from 1006 patients were included. There were 520 (51.7%) patients with susceptible strains, 136 (13.5%) with clarithromycin-resistant strains, 144 (14.3%) with metronidazole-resistant strains and 206 (20.5%) with clarithromycin-resistant and metronidazole-resistant strains. In the presence of double resistance, the cure rate was still high (38/41, 92.7%) when MIC levels were low and it was reduced (94/112, 83.9%) only when MIC levels of both antibiotics were high. The cure rates did not significantly differ between patients with single antibiotic-resistant strains, irrespective of MIC values, and those with susceptible strains. CONCLUSIONS: We found that MIC levels of resistance to either clarithromycin or metronidazole play a role in H. pylori therapy outcome and that bacterial resistance becomes relevant in vivo when clarithromycin-resistant and metronidazole-resistant strains have high MIC values for at least one of these antibiotics.
引用
- De Francesco V, Zullo A, Fiorini G, et al. Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication. J Antimicrob Chemother. 2019. PMID: 30476134. doi:10.1093/jac/dky469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。